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EDITORIAL

FSGS: Forme Pleine or Forme Fruste

S

everal years ago, I was asked by a physician-colleague to
conduct a consultation on her spouse who had enjoyed
robust health. Apparently, proteinuria was present, and the
couple was worried. He was a young, adult, white man: no
hypertension, no edema, normal serum creatinine, an
absence of erythrocyturia and lipiduria, and a urine
protein-to-creatinine ratio between 0.6 and 1.0 g of total
protein per gram of creatinine were reported. The ratio of
the urine albumin-to-creatinine ratio to the urine proteinto-creatinine ratio was nearly 0.7 g albumin-to-total protein
(normal range ,0.4), indicating that the bulk of proteinuria
was albuminuria. All the usual serologic assays and hepatitis antibody assays were unrevealing. The patient was
35 years old and “needed to know” what the diagnosis
was. So, an ultrasound-guided kidney biopsy was
conducted. The glomerular histology was established: focal
and segmental glomerulosclerosis (FSGS), with a tip
lesion.1 Minimal tubulointerstitial disease favored
longevity for the patient’s parenchyma. However, the patient was informed that kidney failure was in his horizon.
Recalling that FSGS, ﬁrst described in 1957, is a lesion with
variations and not a disease, it was important to establish a
diagnosis in this patient who had manifested a rather
nonclassical presentation.
In retrospect, it would have been unlikely that the histology would have been FSGS had the PCR been less than
0.5—an important guide to the clinical evaluation.2 However, this criterion was established in children and not in
adults. Interestingly, with aging, adults incur an increase
in albumin-to-creatinine ratio, and this has been attributed
to a diminution of the denominator of this ratio, but what if
the numerator was increasing instead with aging. Interestingly, in Munich-Wistar-Fromter rats, loss of the vascular
endothelial glycocalyx in nonkidney and kidney vessels
occurs in association with aging and accounts for a
10-fold increase in albuminuria. This observation was subtotally mitigated by feeding of Munich-Wistar-Fromter
rats with wheat germ agglutinin lectin and consequent
re-establishment of the endothelial glycocalyx.3 In older,
bodyweight-matched Wistar rats, there was not a statistically signiﬁcant increase in albuminuria with aging,
although urinary total protein tripled. Although the rat
may not represent an ideal model for human disease, glycocalyx restoration therapy in man is potentially tenable

for certain glomerulopathic states characterized by glycocalyx disruption, such as diabetes.
The patient was HIV negative and was not AfricanAmerican. He did not ﬁt the phenotype of Alonzo Mourning or Sean Elliott whose illustrious, professional basketball
careers were interrupted by full-blown nephrotic syndrome
from FSGS (forme pleine). Remarkably, both played competitively, despite signiﬁcant illness, up until the point of kidney transplantation. After allograft implantation, neither
individual had immediate recurrence of their disorder as
Hoyer described 3 decades ago.4 However, the absence of
disease recurrence does not imply that either of these
individuals were absent of any circulating glomeruloproteinuric factor. Two have been identiﬁed: soluble urokinaseplasminogen activating receptor that engages the podocyte
beta-3 integrin receptor and induces podocytes to become
ﬂat-footed with proteinuria5 and the interleukin-6 family
member, cardiotrophin-like cytokine-1 (CLC-1, SavinSharma factor), that exponentially increases glomerular
albumin permeability.6 In fact, the majority of such cases
of FSGS do not recur in the kidney allograft, although
when relapse ensues, it may manifest itself quite sharply
and immediately.
My patient had something else. His presentation was
subtle, almost unstructured (forme fruste). He had never
used heroin, and this agent among others has been implicated in the 1960s and 1970s as causative of FSGS.7 Drug
purity appears important in so-called heroin-associated nephropathy, but adulterants more than the putative agent
represent a viable causative alternative.6 Although the patient was muscular, he was not a competitive bodybuilder.
Nonetheless, the question of anabolic steroid use arose.
Recently, proteinuria and bodybuilding have been linked,
with anabolic steroids as pathogenic for FSGS.8 Ten bodybuilders, 6 white and 4 Hispanic, with proteinuria and a
long history of anabolic steroid use, had kidney biopsyproven FSGS: 3 with collapsing FSGS and 4 with perihilar
lesions. Glomerulomegaly appeared in 4 biopsy specimens; in 1 patient, this was the sole lesion. Withdrawal
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of the offending agent led to a partial clinical resolution in
most cases. Relapsing disease on voluntary but ill-advised
drug readministration occurred in 1 patient.
The exact etiopathogenic sequence of anabolic steroidinduced kidney injury has not been delineated, but the
combination of excessive lean body mass plus anabolic
steroid use may be causative in this mesomorphic proteinuric disorder. Whether hyperﬁltration is attendant to this
disorder, as it is in obesity-related glomerulosclerosis, has
not been discerned to date. Importantly, the concept that
proteinuria could only induce kidney damage through
hyperﬁltration had been overturned much earlier. It had
already been documented by Tapp and colleagues9 in
1989 that calories, not protein intake, induced equal
amounts of kidney parenchymal damage in an animal
model of hyperﬁltration. In summary, anabolic steroidrelated FSGS should be considered in muscular athletes
who demonstrate signiﬁcant proteinuria, namely beyond
that of exercise-induced proteinuria.
Note that the 2 basketball players mentioned before are
black, and although they differed greatly in muscle mass
(Mourning, highly muscular; Elliott, slim), they had the
same disorder. Plausibly, these 2 individuals were similarly predisposed to FSGS by inheritance of one of the kidney risk alleles of the apolipoprotein L1 gene (APOL1)—a
recently evolved member of the APOL gene family with 2
allelic variants, G1 and G2, that confer protective
trypanolytic activity at the expense of enhanced risk for
glomerular damage.10,11 The increased risk of CKD in
susceptible individuals is estimated at 7- to 30-fold for a
subset of black individuals with G1 or G2 haplotypes.
The risk is disproportionately greater in those afﬂicted
with FSGS and HIV-associated nephropathy and hypertensive nephrosclerosis. In 2 trials of CKD, AASK (African
American Study of Kidney Disease), and CRIC (Chronic
Renal Insufﬁciency Cohort), Parsa and his coinvestigators
determined greater rates of end-stage kidney disease and
progression of CKD in black patients, with kidney risk
variants of APOL1, compared with white patients (hazard
ratio 1.88).12 This is concordant with the results of genetic
studies that estimate that 50% of African Americans harbor either 1 or 2 risk alleles and that 10% to 15% have 2
alleles.11 In brief, although not a classical Mendelian disorder, APOL1 gene mutations functionally act as such.
Several world class, African American bodybuilders had
developed FSGS with kidney failure, previously. Steroids
were blamed. Quite possibly, multiple stressors were at
play. These individuals may have harbored the APOL1
risk alleles, self-imposed hyperﬁltration from protein
ingestion of 300 g daily, and added the injurious effects
of anabolic steroids.
The clinical diagnosis of the patient was possibly primary
FSGS. Depending on the classiﬁcation scheme, primary
could mean a congenital cause of FSGS. Per National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative,13 this would include such causes, but not so
by KDIGO (Kidney Disease: Improving Global Outcomes).14 As a middle-aged adult, it was unlikely that he
had concealed for decades of one of the pediatric, steroidresistant, gene mutation-induced podocytopathies that
produce an FSGS lesion. These podocytopathies include

derangements of multiple, structural proteins15: slit
diaphragm protein, nephrin16; the stomatin protein
family member, podocin, which is generally associated
with congenital and childhood nephrosis17 and is a raftassociated component of the slit diaphragm that interacts
with nephrin and CD2-associated protein (CD2AP), a scaffolding protein that regulates the actin cytoskeleton18;
Wilm tumor-119; and ras-activating phospholipase C,
epsilon-1 (PCLE1).20-22
In contrast, he may have been harboring one of the
autosomal dominant gene mutations: laminin beta-2
(LAMB2),23 alpha-actinin-4 (ACTN2),24 transient receptor
potential cation channel 6 (TRPC6),25 or the actinregulating, inverted formin gene 2 (INF2).26 LAMB2 nephropathy was unlikely as it and nephrin-, podocin-, and
WT1-related FSGS generally manifest in the ﬁrst year of
life. ACTN2 and TRPC6 disorders stem from extremely
rare gene mutations that produce disease in adults. INF2
disease covers a broad range of ages, however, from the
teenage to the elderly population in those of European
ancestry. To distinguish among these possibilities, molecular biology tools would be required.
Secondary FSGS seemed unlikely, and the patient was
neither diabetic nor in the age category of those who
develop a monoclonal gammopathy with nodular glomerulosclerosis. There was no history of chronic bisphosphonate
administration or an HIV infection: no collapsing glomeruli,
proliferating parietal cells,27 or reticular inclusion bodies detected in the biopsy specimen. The history was absent prior
and remote glomerular tuft insult with residua of remnant
scarring and proteinuria, attributable to incomplete restoration of the vascular endothelium, glomerular basement
membrane, or investing glomerular visceral epithelial
cells—podocytes that are subjected to multiple traumatic
stressors and reticent to repopulate themselves.
Recently, support for the clinical observation that FSGS
as a secondary lesion may follow a prior kidney injury,
such as vesicoureteral reﬂux, has been experimentally
veriﬁed. Glomerular deposition of “natural” immunoglobulin M (IgM) with consequent activation of cognate
C3 ligand was demonstrated in 3 different animal models
of glomerular injury induced by adriamycin-induced
toxicity.28 Previously, the presence of C1q and C3 deposition, usually in the mesangial compartment, had been
thought somewhat “incidental.” Attenuation of albuminuria followed B-cell depletion after anti-murine CD20
antibody, peritoneal B-cell depletion after hypotonic
shock, and in a strain of genetically B-cell-depleted
mice (Jh). IgM deposition was reduced in all 3 models.
These observations reconcile in part the somewhat
enigmatic entity of IgM nephropathy and its variable responsivity to glucocorticoid steroids.15
In the end, the cause of the patient’s FSGS was uncovered. The patient’s diagnostic evaluation had required genetic analysis, under the auspices of The Nephrotic
Syndrome Study Network [NEPTUNE], led by Matthias
Kretzler at the University of Michigan. The comprehensive system-based approach used in the Kretzler
laboratory is enriched and empowered by multiple collaborators in diverse biologic and computational ﬁelds and
has determined other disease variants of minimal change
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disease and FSGS. There was a compound heterozygous
mutation of the podocin gene (R229Q), a forme fruste of
FSGS. Clinical expression of autosomal recessive podocin
mutations is contingent on the speciﬁc mutation in each of
the parental copies of the gene. In other words, podocininduced FSGS is subject to multiple allelism.29 Compound
heterozygosity for R229Q in conjunction with a podocin
mutation is now a cause of steroid-resistant nephrotic syndrome of young adults. Today, the patient remains
normotensive and albuminuria is mild. The estimated
glomerular ﬁltration rate remains .60 mL/min/1.73 m2,
and he is relieved that he does not have classical FSGS.
Impassioned and inspired by the science behind his kidney problem, the patient developed an enthusiastic,
enduring relationship with the NephCure Foundation,30
the sole, nonproﬁt public charity devoted to supporting
research of nephrotic syndrome and FSGS. To support
the NephCure community, the patient shares his story to
help others (and their families) who had FSGS or
nephrotic syndrome.
FSGS has been running into me for many years. Certainly,
the clinical course of FSGS is not always that which has
been written into the classical texts since its initial description in 1957 by Rich,31 and that is the progress. “The more I
learn, the more I realize how much I don’t know.”—A.E.
Truly. FSGS has been an abiding part of my life as a
nephrologist, and it will continue to be so. “That’s just the
way it is, it is, it is, it is.”—B.H.
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